A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : HER3 / human epidermal growth factor receptor 3

[Related PubMed/MEDLINE]
Total Number of Papers: 73
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   HER3  (>> Co-occurring Abbreviation)
Long Form:   human epidermal growth factor receptor 3
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Antitumor effect of insulin-like growth factor-1 receptor inhibition in head and neck squamous cell carcinoma. HNSCC, IGF1R, OC, RPPA, TKIs
2020 Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers. EGFR, HR, TNBC
2020 Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model. PET/CT
2020 Higher Anti-Tumor Efficacy of the Dual HER3-EGFR Antibody MEHD7945a Combined with Ionizing Irradiation in Cervical Cancer Cells. EGFR, IR, LACC
2020 Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules. HE
2020 Inhibitory Effect of Polyclonal Antibodies Against HER3 Extracellular Subdomains on Breast Cancer Cell Lines. ECD, pAbs
2020 MicroRNA-205 targets HER3 and suppresses the growth, chemosensitivity and metastasis of human nasopharyngeal carcinoma cells. ---
2020 Novel functional anti-HER3 monoclonal antibodies with potent anti-cancer effects on various human epithelial cancers. mAbs
2020 Silencing of CD133 inhibits GLUT1-mediated glucose transport through downregulation of the HER3/Akt/mTOR pathway in colon cancer. CD133
10  2019 Development of a ZHER3-Affibody-Targeted Nano-Vector for Gene Delivery to HER3-Overexpressed Breast Cancer Cells. HER2
11  2019 Elimination of HER3-expressing breast cancer cells using aptamer-siRNA chimeras. eEF2, GRK4, Plk1, RNAi
12  2019 Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake. ---
13  2019 Increase in negative charge of 68Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules. ---
14  2019 Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111. ---
15  2019 Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer. ---
16  2019 [Preparation and identification of single-chain fragment variable against epidermal growth factor receptor 3]. scFv
17  2018 A novel synthetic trivalent single chain variable fragment (tri-scFv) construction platform based on the SpyTag/SpyCatcher protein ligase system. Tri-scFv, tri-scFv
18  2018 Aptamer-drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity. ApDC, DOX
19  2018 Association between the overexpression of Her3 and clinical pathology and prognosis of colorectal cancer: A meta-analysis. CRC, HRs, ORs, OS, TNM
20  2018 Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab. ABD
21  2018 Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs. mAbs
22  2018 Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers. Ad-HER3, ADCC, anti-HER3, CDC, EGFR, HER2, HER3-VIAs
23  2018 Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics. ---
24  2018 Silencing human epidermal growth factor receptor-3 radiosensitizes human luminal A breast cancer cells. IR
25  2017 89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors. PD, PET, SUV
26  2017 A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion. EGFR, HER2, ICDs
27  2017 A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. DLTs, MTD, RDE
28  2017 A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS. AEs, DLTs, EGFR, MAPK, MEK
29  2017 Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancer. HRG, NSCLC, PFS, sHRG
30  2017 Evaluation of a radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 expression. 55Co, p.i
31  2017 HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target? AACR, ASCO, BTCs, ESMO, HER2, HQ, IHC, ISH, LQ
32  2017 Human Epidermal Growth Factor Receptor 3-Specific Tumor Uptake and Biodistribution of 89Zr-MSB0010853 Visualized by Real-Time and Noninvasive PET Imaging. ---
33  2017 In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct. ---
34  2017 LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer. ---
35  2017 Mesenchymal stem cell-conditioned medium promotes MDA-MB-231 cell migration and inhibits A549 cell migration by regulating insulin receptor and human epidermal growth factor receptor 3 phosphorylation. CMs, IRs, MSCs
36  2017 NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells. NRG1, p-Akt, p-HER2, p-HER3, pMAPK
37  2017 Prognostic significance of HER3 in patients with malignant solid tumors. ---
38  2016 Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance. RTK
39  2016 Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE). PFS
40  2016 Efficient [(18)F]AlF Radiolabeling of ZHER3:8698 Affibody Molecule for Imaging of HER3 Positive Tumors. IEDDA, NODA, TCO
41  2016 Human epidermal growth factor receptor 3 in head and neck squamous cell carcinomas. EGFR, HER, HNSCCs, PI3K, TKIs
42  2016 Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases. ALK, IGF1R, NSCLC, TKI
43  2016 Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. ---
44  2016 Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck. NRG1
45  2016 Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study). AEs, CI, EGFR, HPV, NRG1, R/M, SCCHN
46  2016 Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds. ---
47  2016 The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways. EGF, EGFR, HER2, NDRG1
48  2015 Affibody-mediated PET imaging of HER3 expression in malignant tumours. PET
49  2015 Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer. EGFR, HRG, HRs, NSCLC, PFS
50  2015 Comparative evaluation of 111In-labeled NOTA‑conjugated affibody molecules for visualization of HER3 expression in malignant tumors. 111In, p.i, SPECT
51  2015 HER3 over-expression and overall survival in gastrointestinal cancers. CI, OR, OS
52  2015 Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma. HER2, HR, mRNA, OPSCC, OS
53  2015 Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer. NSCLC
54  2015 Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum. ---
55  2014 Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy. NRG1, RTK, TKI
56  2014 Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. PI3K, TNBC
57  2014 Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study. EGFR, ELISA, FISH, HER2, IHC, pCR, PIK3CA, PTEN
58  2014 HER-2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma. EAC, HER2, IHC
59  2014 Imaging of HER3-expressing xenografts in mice using a (99m)Tc(CO) 3-HEHEHE-Z HER3:08699 affibody molecule. ---
60  2014 Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors. AEs, DLTs, PS
61  2014 RETRACTED: An ATP-competitive inhibitor modulates the allosteric function of the HER3 pseudokinase. ---
62  2013 Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation. Abs, PI3K
63  2013 HER3 overexpression and survival in solid tumors: a meta-analysis. CI, ORs, OS
64  2013 Human epidermal growth factor receptor 3 (HER3) blockade with U3-1287/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma. EGFR
65  2011 HER3 overexpression as an independent indicator of poor prognosis for patients with curatively resected pancreatic cancer. CA19-9
66  2010 Analytic variability in immunohistochemistry biomarker studies. EGFR, ER, IHC
67  2008 [Isolation of CD44+/CD24 -/low and side population cells from MDA-MB-453 cells and the analysis of their activation of Wnt and Notch pathway]. HER2, RT-PCR, SP
68  2006 A high-throughput migration assay reveals HER2-mediated cell migration arising from increased directional persistence. HER2
69  2004 Protein tyrosine kinase Syk modulates EGFR signalling in human mammary epithelial cells. EGFR, HER2, PTKs, Syk
70  2004 Role of proneuregulin 1 cleavage and human epidermal growth factor receptor activation in hypertonic aquaporin induction. ---
71  2003 Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3. HRG
72  2002 Expression and transactivating functions of the bZIP transcription factor GADD153 in mammary epithelial cells. ATF, C/EBP, GADD153
73  2002 Heregulin up-regulates heat shock protein-70 expression in breast cancer cells. HSP70